Biotech Values

[DewDiligence]

EVO +17% on extended/expanded collaboration with BMY:

https://www.accesswire.com/700771/Evotec-and-Bristol-Myers-Squibb-Extend-and-Expand-Strategic-Partnership-in-Protein-Degradation

This builds on the deal inked CELG inked with EVO in Apr 2018 that has since been extended and expanded prior to today’s announcement (https://www.evotec.com/en/invest/news--announcements/p/bristol-myers-squibb-exercises-option-to-extend-targeted-protein-degradation-partnership-with-evotec-6057, https://www.accesswire.com/681999/Evotec-Expands-Neuroscience-Collaboration-with-Bristol-Myers-Squibb-to-Include-New-Targeted-Protein-Degradation-Approach ).

With today’s collaboration extension/expansion, EVO gets an additional $200M in up-front cash.